CION Ameerpet
A tumour cannot grow beyond a few millimetres without building itself a blood supply. Anti-angiogenic therapy — the anti-VEGF drug class — interferes with that construction work. It is not chemotherapy, it is not a cure, and it is not for everyone. It is a targeted addition that, in the right situation, keeps ovarian cancer under control for longer and can settle the fluid that makes the abdomen swell.
Every tumour has the same early problem: it cannot grow beyond a few millimetres on diffusion alone. To get bigger it has to build a blood supply, and it does that by flooding the surrounding tissue with a signalling protein called vascular endothelial growth factor, or VEGF. Nearby blood vessels read that signal and sprout new branches towards the tumour. That process is angiogenesis.
Anti-angiogenic therapy is the drug class that interrupts the signal. It does not kill cancer cells the way chemotherapy does. It removes the tumour’s ability to commission new plumbing, and it changes the vessels that already exist — the ones a tumour builds are chaotic and leaky, and blocking VEGF makes them behave more like normal vessels. That second effect matters more in ovarian cancer than in most other cancers, because leaky vessels across the abdominal lining are how ascites forms. Women often notice the abdomen settling before any scan is done.
In practice it is given as an intravenous infusion, usually on the same day as a cycle of platinum-based chemotherapy, and then continued on its own for a defined period after the chemotherapy course finishes. That second phase is what your team means by maintenance — there is more on the whole idea in our guide to maintenance therapy for ovarian cancer.
It acts on the tumour’s blood supply rather than on dividing cells, so the side effects are a completely different set from chemotherapy’s — blood pressure and protein in the urine, not hair loss and low counts.
Starving new vessels slows growth and normalises leaky ones. In ovarian cancer that also means less fluid crossing into the abdominal cavity, which is why ascites often improves early.
This class is used alongside chemotherapy and then continued afterwards. It does not replace surgery, chemotherapy or PARP-inhibitor-class maintenance — it sits with them.
Two large randomised trials — GOG-218 and ICON7 — tested adding anti-angiogenic therapy to first-line platinum-based chemotherapy and continuing it as maintenance in advanced ovarian cancer. Both found that the cancer took several months longer to progress. Neither showed an overall survival benefit for the trial population as a whole, and in ICON7 an exploratory analysis suggested the gain was concentrated in women at high risk of early progression — stage 4 disease, or disease left behind after surgery. That is why this class is offered selectively rather than to everyone with ovarian cancer. Source: Burger RA et al., New England Journal of Medicine (2011); Perren TJ et al., New England Journal of Medicine (2011); NCCN Ovarian Cancer guidelines.
This class is not a standard part of every ovarian cancer plan. It has four recognised places, and one of the most useful things you can ask your oncologist is which of them applies to you.
In advanced disease it can be added to platinum-based chemotherapy and continued alone once the chemotherapy course ends, typically for up to about a year to fifteen months in the trials that defined the schedule. The aim is to lengthen the remission rather than to change what the chemotherapy itself achieves.
It is chosen most readily where the risk of early return is higher — stage 4 disease, disease that could not all be removed at surgery, or a large volume of ascites at diagnosis. Where a woman has had complete removal of stage 3 disease and a rapid marker response, the case for adding it is weaker, and a candid oncologist will say so rather than add it by default.
If the cancer returns more than six months after platinum-based chemotherapy finished, it is usually treated with platinum-based chemotherapy again. Adding anti-angiogenic therapy to that combination, and continuing it afterwards, has been shown in randomised trials to delay the next progression.
The decision here often turns on what was used before. If this class was given first-line and the disease progressed while on it, repeating it makes less sense. If it was never used, or there was a long gap, it becomes a reasonable addition. This is also the point where PARP-inhibitor maintenance enters the conversation, and the two classes have to be sequenced rather than both reached for at once.
Where the cancer returns within six months of platinum-based treatment, single-agent chemotherapy is the usual route, and response rates are modest. A randomised trial found that adding anti-angiogenic therapy to single-agent chemotherapy in this setting improved response and delayed progression, and — unusually for a trial in resistant disease — improved reported symptoms.
That symptom effect is the honest reason many oncologists use it here. Ascites, abdominal pressure and breathlessness are what make platinum-resistant disease hard to live with, and this class acts directly on the mechanism behind them.
Ascites is fluid leaking from abnormal vessels across the peritoneum. Blocking VEGF reduces that leak, and in practice many women need drainage less often once treatment starts. It is not licensed as a treatment for ascites on its own, but the effect is real and it is frequently part of why the class is chosen.
If repeated drainage is dominating your months, it is worth asking directly whether this class could reduce how often it is needed. That is a specific, answerable question, and it changes daily life more than a line on a survival curve does.
It is a day-unit infusion, usually every three weeks alongside chemotherapy and then on the same rhythm during maintenance. The infusion itself takes between half an hour and ninety minutes; the first one is given slowly and later ones are shortened if it is well tolerated. There is no tablet form of this class.
Before each dose your blood pressure is measured and your urine is dipped for protein. Those two checks catch almost everything this class does quietly, and they are the reason a dose is sometimes held. Chemotherapy and maintenance infusions are delivered in-house at CION across 35+ centres, so this monitoring happens wherever you are being treated rather than only at one hospital.
There are situations where the risk clearly outweighs the gain: uncontrolled high blood pressure, significant protein loss in the urine, recent serious bleeding, a recent stroke or heart attack, or a wound that has not healed. Surgery in the near future is another — this class delays wound healing, so it has to be stopped several weeks before an operation and not restarted until healing is complete.
The one that needs naming plainly is bowel involvement. Where tumour is on or in the bowel wall, or where there has been an obstruction or recent bowel surgery, the risk of a perforation is meaningfully higher. It is uncommon, and it is serious, and it is the single reason most often given for not using this class in advanced ovarian cancer.
None of these means treatment is failing. Each is a reason to ring the day-care unit the same day rather than wait for the next cycle — which is exactly why you are given a 24-hour number.
Sudden, severe abdominal pain with fever or persistent vomiting needs same-day assessment. Perforation of the bowel is uncommon on this class, and it is the one that must never wait.
Raised blood pressure is the commonest effect and usually responds to tablets. Check at home if you have a monitor, and report readings that stay high rather than waiting for the next visit.
Both can mean protein leaking through the kidney filters. It is picked up on a routine dipstick, but tell the team if you notice it between doses.
Nosebleeds and bleeding gums are common and mild. Coughing or vomiting blood, or any heavy bleeding, needs urgent assessment the same day.
Could be a clot, or fluid around a lung. Both are treatable and both are worse for being left over a weekend.
This class slows healing. A surgical wound, a drain site or a tooth extraction that opens, oozes or stays raw should be reported before the next dose is given.
Keep the unit’s number saved in your phone and tell whoever is at home with you where it is. Most of these calls end in reassurance — and the few that do not are exactly the ones that needed making.
Bring your CT report, your pathology result, your CA-125 values and your BRCA or HRD report if you have one. In 45 minutes a medical oncologist can explain what adding anti-angiogenic therapy is expected to achieve in your case, what it would ask of you, and what it will cost.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. If this class would add side effects without adding much for you, we will say so plainly rather than add it because it is available.
These are the two maintenance classes used in ovarian cancer, and they are chosen on different grounds. This is the comparison women most often want and least often get in a ten-minute appointment.
| What is being compared | Anti-angiogenic (anti-VEGF) class | PARP-inhibitor class |
|---|---|---|
| What it targets | The tumour’s blood supply — VEGF signalling and the new vessels it builds. | DNA repair inside the cancer cell, exploiting a repair weakness the tumour already has. |
| Who it is chosen for | Chosen on clinical risk — stage 4 disease, disease left after surgery, heavy ascites. Not selected on genetics. | Chosen on BRCA and HRD status. The benefit is largest in BRCA-related and HRD-positive cancers. |
| How it is taken | Intravenous infusion in a day unit, usually every three weeks. | Tablets or capsules taken at home every day. |
| When it starts | Alongside chemotherapy, then continued after it finishes. | After chemotherapy has finished and a response has been confirmed. |
| Main things to watch | Blood pressure, protein in the urine, bleeding, delayed wound healing, bowel perforation (uncommon). | Low blood counts, nausea and fatigue, needing regular blood tests, particularly in the first few months. |
| Around surgery | Must be stopped several weeks before and after any operation. | Usually paused around surgery, but wound healing is not the constraint. |
| Can they be combined? | Yes, in selected cases — a randomised trial found combined maintenance delayed progression in HRD-positive cancers. | Same trial, same answer. Combination is a specialist decision, not a default. |
*Neither class is a cure, and neither is automatically the better one. The choice is made from your BRCA and HRD results, the stage and the completeness of surgery, and what you can live with day to day — discussed at a tumour board rather than decided in a corridor. Our guide to maintenance therapy covers the wider decision.
Most women arrive with one of two questions. Either they have been offered this class and want to know whether it is worth the extra months of infusions and monitoring, or it has not been mentioned at all and they have read about it since. Both deserve a proper answer, and both take longer than a ten-minute review slot allows.
Your first consultation at CION is free and runs to about 45 minutes. Bring the CT report, the pathology result, your CA-125 values and your BRCA or HRD report if it has been done. What usually needs unpicking is specific: whether your risk profile is the kind that benefited in the trials, whether your bowel is involved in a way that makes this class unwise, and how it should be sequenced against PARP-inhibitor-class maintenance so that neither is wasted. Every case is discussed at a tumour board rather than decided by one doctor alone.
We should be clear about who does what. Chemotherapy and maintenance therapy, including anti-angiogenic infusions, are delivered in-house at CION across 35+ centres in Telangana and Andhra Pradesh, along with genetic counselling, BRCA and HRD testing, nutrition support, survivorship care and follow-up. Cytoreductive surgery is coordinated with specialist gynaecologic-oncology partner centres, where it is performed and may be billed. That matters practically here, because this class has to be stopped several weeks before an operation and restarted only once the wound has healed — the timing has to be agreed between the surgical and medical teams, and coordinating it is part of the job.
On cost: this class is given for months rather than weeks, so it is a real financial decision and not only a clinical one. Biosimilar versions are widely available in India and have brought the cost down considerably compared with the originator product. We put the expected cost of a full course in writing before it starts, including the monitoring, so that the decision is made with the number in front of you. Ask for a cost estimation at your first visit — or read our overview of ovarian cancer treatment in Hyderabad first.
Free and unhurried. Long enough to work out whether your particular risk profile is one this class was shown to help, rather than assuming it is.
Medical oncology, imaging and pathology decide maintenance together, including how the two maintenance classes should be sequenced for you.
Chemotherapy and maintenance infusions, with the blood pressure and urine checks that go with them, at whichever of our 35+ centres is closest to you.
A months-long treatment deserves a written estimate before it begins. Decisions for healing, not billing — including the decision not to add something.
*Anti-angiogenic therapy is not appropriate for everyone with ovarian cancer, and it is not offered on request. Whether it belongs in your plan depends on your imaging, your surgery, your other conditions and your BRCA and HRD results — book a free consultation to have that assessed properly.
It is a class of targeted treatment that blocks vascular endothelial growth factor, or VEGF — the signal a tumour sends out to build itself new blood vessels. Without that signal, new vessels do not form and existing ones become less leaky, so the tumour is starved of supply and grows more slowly. It is given as an intravenous infusion, usually every three weeks, most often alongside platinum-based chemotherapy and then continued alone as maintenance for a defined period. It is not chemotherapy and it does not directly kill cancer cells. In ovarian cancer it has a second, very practical effect: because ascites forms when abnormal vessels leak fluid into the abdominal cavity, blocking VEGF often reduces that fluid and the swelling and pressure that come with it.
No. Chemotherapy attacks rapidly dividing cells, which is why it causes hair loss, low blood counts, mouth soreness and nausea. Anti-angiogenic therapy acts on the blood vessels feeding the tumour, so it has a completely different side-effect profile: raised blood pressure, protein in the urine, nosebleeds, delayed wound healing, and a small risk of clots or bowel perforation. It is given by infusion in the same day unit and often on the same day as chemotherapy, which is why the two are easily confused. When chemotherapy finishes, this class can continue on its own for months as maintenance. During that phase most women feel well, work, and get on with normal life, with a short visit every three weeks for the infusion and the routine checks.
No, and this is the main practical difference from the other maintenance class. PARP-inhibitor-class maintenance is chosen on genetics: the benefit is largest in BRCA-related and HRD-positive cancers, so the test result drives the decision. Anti-angiogenic therapy is chosen on clinical risk instead — stage 4 disease, disease left behind after surgery, a large volume of ascites — and it works irrespective of BRCA status. That makes it an option for women whose genetic results do not point towards PARP-inhibitor-class treatment. It also means both classes can be relevant at once, and in selected HRD-positive cancers a randomised trial found that giving them together as maintenance delayed progression further than one alone. Combining them is a specialist decision rather than a default.
The honest answer is that it reliably delays the cancer coming back, and has not been shown to extend overall survival across whole trial populations. In the two large first-line trials, adding it to chemotherapy and continuing it as maintenance pushed progression back by several months without an overall survival gain for the group as a whole, though an exploratory analysis suggested women at high risk of early progression benefited more. In platinum-resistant recurrence, adding it improved response, delayed progression and improved reported symptoms. Delaying progression is not nothing — it can mean months without treatment, without drainage and without new symptoms. But it is a different claim from living longer, and any team offering this class should make that distinction for you rather than blur it.
Expect your blood pressure to be checked and your urine dipped for protein before every dose, because raised blood pressure is the commonest effect and protein leak the next. Both usually respond to tablets or a held dose. Nosebleeds, bleeding gums, tiredness, a hoarse voice and slower healing of small wounds are common and mild. Ring the unit the same day for severe abdominal pain with fever or vomiting, heavy bleeding or blood in vomit or sputum, sudden breathlessness, chest pain, calf swelling, or a wound that opens or will not heal. Severe abdominal pain matters most: perforation of the bowel is uncommon on this class, but it is serious and it must not wait until the next appointment.
In first-line treatment it is generally given alongside chemotherapy and then continued as maintenance for up to about a year to fifteen months, which is the schedule the trials used. In recurrent disease it is often continued until the cancer progresses or side effects make stopping sensible. Surgery is the one thing that firmly interrupts it. Because this class slows wound healing, it has to be stopped several weeks before a planned operation and not restarted until the wound has fully healed, usually at least four weeks afterwards. That gap needs planning rather than improvising. At CION, cytoreductive surgery is coordinated with specialist gynaecologic-oncology partner centres, so the timing is agreed between the surgical and medical teams in advance.
The first consultation is free and runs to about 45 minutes. CION delivers medical oncology for ovarian cancer in-house: chemotherapy and maintenance therapy, including anti-angiogenic infusions and the blood pressure and urine monitoring that go with them, across more than 35 centres in Telangana and Andhra Pradesh, along with genetic counselling, BRCA and HRD testing, nutrition support, survivorship care and follow-up. Cytoreductive surgery is coordinated with specialist gynaecologic-oncology partner centres, where it is performed and may be billed — we state that upfront rather than leave it to be discovered later. Every case is discussed at a tumour board, and because this class runs for months, the expected cost of the full course is put in writing before treatment starts.